Literature DB >> 18690502

Cyclophosphamide-based combination therapies for autoimmunity.

Paola Perini1, Massimiliano Calabrese, Luciano Rinaldi, Paolo Gallo.   

Abstract

Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNbeta) have also been successfully applied to treat IFNbeta-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18690502     DOI： 10.1007/s10072-008-0947-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  12 in total

1.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.

Authors:  K E Balashov; D R Smith; S J Khoury; D A Hafler; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.

Authors:  D R Smith; K E Balashov; D A Hafler; S J Khoury; H L Weiner
Journal:  Ann Neurol       Date:  1997-09       Impact factor: 10.422

Review 3.  Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases.

Authors:  J Kovarsky
Journal:  Semin Arthritis Rheum       Date:  1983-05       Impact factor: 5.532

4.  A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.

Authors:  D R Smith; B Weinstock-Guttman; J A Cohen; X Wei; C Gutmann; R Bakshi; M Olek; L Stone; S Greenberg; D Stuart; J Orav; W Stuart; H Weiner
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

5.  Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis.

Authors:  F Patti; M L Cataldi; F Nicoletti; E Reggio; A Nicoletti; A Reggio
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

6.  Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.

Authors:  Francesco Patti; Ester Reggio; Filippo Palermo; Teresa Fiorilla; Guido Politi; Alessandra Nicoletti; Arturo Reggio
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

7.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

Review 8.  Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease.

Authors:  D T Boumpas; H A Austin; B J Fessler; J E Balow; J H Klippel; M D Lockshin
Journal:  Ann Intern Med       Date:  1995-06-15       Impact factor: 25.391

9.  Immunosuppressive treatment in multiple sclerosis.

Authors:  Howard L Weiner
Journal:  J Neurol Sci       Date:  2004-08-15       Impact factor: 3.181

Review 10.  The safety profile of cyclophosphamide in multiple sclerosis therapy.

Authors:  Paola Perini; Massimiliano Calabrese; Luciano Rinaldi; Paolo Gallo
Journal:  Expert Opin Drug Saf       Date:  2007-03       Impact factor: 4.250
View more
  6 in total

1.  Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Authors:  Charles M Rudin; John T Poirier; Neil N Senzer; Joseph Stephenson; David Loesch; Kevin D Burroughs; P Seshidhar Reddy; Christine L Hann; Paul L Hallenbeck
Journal:  Clin Cancer Res       Date:  2011-02-08       Impact factor: 12.531

2.  Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis.

Authors:  K Mangano; A Nicoletti; F Patti; M Donia; L Malaguarnera; S Signorelli; G Magro; V Muzio; B Greco; P Zaratin; P Meroni; M Zappia; F Nicoletti
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

3.  Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response.

Authors:  Jennifer L Johnson; Loredana Stoica; Yuwei Liu; Ping Jun Zhu; Abhisek Bhattacharya; Shelly A Buffington; Redwan Huq; N Tony Eissa; Ola Larsson; Bo T Porse; Deepti Domingo; Urwah Nawaz; Renee Carroll; Lachlan Jolly; Tom S Scerri; Hyung-Goo Kim; Amanda Brignell; Matthew J Coleman; Ruth Braden; Usha Kini; Victoria Jackson; Anne Baxter; Melanie Bahlo; Ingrid E Scheffer; David J Amor; Michael S Hildebrand; Penelope E Bonnen; Christine Beeton; Jozef Gecz; Angela T Morgan; Mauro Costa-Mattioli
Journal:  Neuron       Date:  2019-10-01       Impact factor: 17.173

4.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

5.  Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.

Authors:  Yayoi Sato-Okabayashi; Kikuo Isoda; Beate Heissig; Tomoyasu Kadoguchi; Koji Akita; Kenichi Kitamura; Kazunori Shimada; Koichi Hattori; Hiroyuki Daida
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-10

6.  The ethanol extract of the inner bark of Caesalpinia pyramidalis (Tul.) reduces urinary bladder damage during cyclophosphamide-induced cystitis in rats.

Authors:  Janaína P Moraes; Denyson S Pereira; Alexandre S Matos; Danielle G Santana; Cliomar A Santos; Charles S Estevam; Ricardo Fakhouri; Waldecy de Lucca Junior; Enilton A Camargo
Journal:  ScientificWorldJournal       Date:  2013-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.